Scroll Top

An RPM Business Augmented by R&D

We are a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. We use our innovative medical device technology with a disruptive business model as an RPM provider to offer the only RPM program with remote wheeze detection for respiratory disorders as well as a broad number of serious chronic conditions.

Respiri’s globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally.

A Lifelong Partner For Our Patients.


As a differentiated RPM provider, our mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, wheeze detection for respiratory disease.


We are Respectful

We are Accountable

We are One Team

We are Innovative

Investor Information

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an Australian e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US healthcare market.

Respiri is listed on the Australian Securities Exchange (ASX) and trades on the OTCQB under the ticker “RSHUF” for North American based investors

Analyst coverage and research
Edison - Analyst coverage and research
MST Access - Analyst coverage and research

You are about to leave this website.

Respiri LTD is not responsible for the content or policies on the linked website.

Do you wish to continue?